BACKGROUND: Many questions remain regarding the pathogenesis, natural history, diagnosis, and treatment of chronic thromboembolic pulmonary hypertension in patients. To answer such questions, we developed an animal model of this disorder. The brisk thrombolytic response of canines to acute embolism has, previously, prevented the establishment of such a model. METHODS AND RESULTS: The fibrinolytic inhibitor tranexamic acid was given orally to canines before, and for intervals after, pulmonary emboli were released from venous thrombi formed in vivo in femoral veins or the inferior vena cava. Preliminary studies disclosed that embolic residuals from femoral vein thrombi were not sufficient to cause significant, persistent pulmonary hypertension. With repetitive, larger thrombi embolized from the inferior vena cava, however, persistent pulmonary hypertension was achieved in most animals. CONCLUSIONS: Resolution of emboli in the canine can be inhibited by tranexamic acid. As in humans, a spectrum of embolic residuals is encountered, and the perfusion lung scan consistently underestimates the extent of embolic residuals. Studies of this animal model continue.
BACKGROUND: Many questions remain regarding the pathogenesis, natural history, diagnosis, and treatment of chronic thromboembolic pulmonary hypertension in patients. To answer such questions, we developed an animal model of this disorder. The brisk thrombolytic response of canines to acute embolism has, previously, prevented the establishment of such a model. METHODS AND RESULTS: The fibrinolytic inhibitor tranexamic acid was given orally to canines before, and for intervals after, pulmonary emboli were released from venous thrombi formed in vivo in femoral veins or the inferior vena cava. Preliminary studies disclosed that embolic residuals from femoral vein thrombi were not sufficient to cause significant, persistent pulmonary hypertension. With repetitive, larger thrombi embolized from the inferior vena cava, however, persistent pulmonary hypertension was achieved in most animals. CONCLUSIONS: Resolution of emboli in the canine can be inhibited by tranexamic acid. As in humans, a spectrum of embolic residuals is encountered, and the perfusion lung scan consistently underestimates the extent of embolic residuals. Studies of this animal model continue.
Authors: George A Alba; Deepak Atri; Sriranjani Darbha; Inderjit Singh; Victor F Tapson; Michael I Lewis; Hyung J Chun; Yen-Rei Yu; Bradley A Maron; Sudarshan Rajagopal Journal: Curr Cardiol Rep Date: 2021-08-19 Impact factor: 2.931
Authors: Timothy A Morris; James J Marsh; Peter G Chiles; William R Auger; Peter F Fedullo; Virgil L Woods Journal: Am J Respir Crit Care Med Date: 2006-03-02 Impact factor: 21.405
Authors: Olaf Mercier; Adriano Tivane; Peter Dorfmüller; Marc de Perrot; François Raoux; Benoît Decante; Saadia Eddahibi; Philippe Dartevelle; Elie Fadel Journal: Pulm Circ Date: 2013-12 Impact factor: 3.017
Authors: Moritz Brandt; Eleni Giokoglu; Venkata Garlapati; Madgalena L Bochenek; Michael Molitor; Lukas Hobohm; Tanja Schönfelder; Thomas Münzel; Sabine Kossmann; Susanne H Karbach; Katrin Schäfer; Philip Wenzel Journal: Oxid Med Cell Longev Date: 2018-06-10 Impact factor: 6.543
Authors: Ashley Mulchrone; Heidi B Kellihan; Omid Forouzan; Timothy A Hacker; Melissa L Bates; Christopher J Francois; Naomi C Chesler Journal: Front Cardiovasc Med Date: 2019-01-09